Table 8.
Drug dosages with duration
| Serial no | Authors | Treatment | ||
|---|---|---|---|---|
| Drugs | Dose | Duration | ||
| 1 | Po Fung Wong et al. (2020) | Amoxicillin (oral) | 500 mg | Three times per day |
| Paracetamol (oral) | 1 g | Four times per day | ||
| Gabapentin (oral) at discharge | 300 mg | Twice per day | ||
| 2 | Adelaide Panariello et al. (2020) |
Haloperidol, promazine, intranasal midazolam, oral quetiapine with no clinical response. Antibiotic prophylactic therapy was started. High doses of dexamethasone and IVIG were administered. |
NA | NA |
| 3 | Al Olama et al. (2020) | NA | NA | NA |
| 4 | Chaumont et al. (2020) | Acyclovir infusions | NA | Three days |
| Hydroxychloroquine sulphate | 200 mg | 3 times per day for 7 days | ||
| Azithromycin | 250 mg | Once daily for 7 days | ||
| 5 | Andrea Pilotto et al. (2020) | NA | NA | NA |
| 6 | Rong Yin et al. (2020) |
Arbidol, Ribavirin antiviral therapy, traditional Chinese medicine |
NA | NA |
| 7 | Gary McAbee et al. (2020) | NA | NA | NA |
| 8 | Sandeep Sohal and Mansoor Mosammat (2020) |
Hydroxychloroquine, Azithromycin, Vancomycin, Piperacillin tazobactam, Levetiracetam, Valproate |
NA | NA |
| 9 | Rebecca Packwood et al. (2020) |
Acyclovir, Vancomycin, Ceftriaxone, Doxycycline |
NA | NA |
| Lopinavir/Ritonavir | NA | NA | ||
| Hydroxychloroquine and Azithromycin | NA | 6 day course | ||
| Remdesivir | NA | NA | ||
| 10 | Charcon Aguilar et al. (2020) | NA | NA | NA |
| 11 | Hale Afshar et al. (2020) |
Broad spectrum IV antibiotics: Meropenem Levofloxacin Linezolide |
1 g 750 mg 600 mg |
Thrice daily Daily Twice daily |
|
Hydroxychloroquine Atazanavir |
400 mg 200 mg 400 mg |
Twice for first day Twice Daily |
||
| IVIG |
25 g/day later 3 g/kg body weight (250 g total) |
3 days | ||
| Levetiracetam (IV) | 500 mg | Twice daily | ||
| Methylprednisolne (IV) | 500 mg/day | 6 days | ||
| 12 | Ye et al. (2020) |
Arbidol, Mannitol infusion |
NA | NA |
| 13 | Narges Karimi et al. (2020) |
Phenytoin (IV), Levetiracetam (IV) |
||
| Chloroquine | 200 mg | Twice daily | ||
| Lopinavir/Ritonavir | 400/100 mg | Twice daily | ||
| 14 | Ibrahim Efecan Efe et al. (2020) | NA | NA | NA |
| 15 | Duong et al. (2020) |
Antibiotics: Vancomycin, Ceftriaxone |
NA | 3 days |
| Acyclovir | NA | NA | ||
| Anti-epileptics (not mentioned) | NA | NA | ||
| Hydroxychloroquine | NA | NA | ||
| 16 | Moriguchi et al. (2020) |
Ceftriaxone (IV), Vancomycin (IV), Acyclovir (IV), Steroids (IV) Favipiravir (IV) |
NA |
NA 10 days |
| 17 | Misayo Hayashi et al. (2020) | Sulbactam/ampicillin | 1.5 g | Twice per day |
|
Favipiravir, Corticosteroid pulse, Ciclesonide, Meropenem |
NA | NA | ||
| 18 | Pilotto et al. (2020) |
Lopinavir/Ritonavir Hydroxychloroquine |
400/100 mg 200 mg |
Twice daily Twice daily |
|
High dose IV steroid: Methylprednisolone |
1 g/day | 5 days | ||
| 19 | Dogan et al. (2020) |
Lopinavir/Ritonavir, Azithromycin, Ceftriaxone, Hydroxychloroquine, Favipiravir, Plasmapheresis cycles |
NA | NA |
| 20 | Debaleena Mukherjee et al. (2020) | Intravenous antibiotics and other supportive therapy | NA | NA |
| 21 | Raphael Bernard-Valnet et al. (2020) |
Patient 1: Clonazepam and Valproate (IV) |
NA | NA |
|
Patient 2: Ceftriaxone, Amoxicillin, Acyclovir |
NA | NA | ||
| 22 | Morassi et al. (2020) | NA | NA | NA |
| 23 | Guy Talmor et al. (2020) |
Azithromycin, Hydroxychloroquine |
NA | NA |
| 24 | Romero Sanchez (2020) |
Most commonly used combination: Hydroxychloroquine, Lopinavir/Ritonavir, N-acetylcysteine, Azithromycin |
NA | NA |
| Emtricitabine/Tenofovir or Ribavirin (replacing Lopinavir/Ritonavir) | NA | NA | ||
|
Antibiotics: Levofloxacin, Doxycycline, Ceftriaxone, Teicoplanin |
||||
|
Corticosteroid IV: Methylprednisolone |
125 mg, 250 mg > 250 mg |
NA | ||
|
Immunomodulatory therapy: Beta-interferon, Baricitinib, IVIG, Anakinra |
NA | NA | ||
| 25 |
Andrea Pilotto et al. (2020) [The clinical spectrum of encephalitis in COVID-19 disease: the ENCOVID multicentre study] |
Hydroxychloroquine, Antiviral |
NA | NA |
| 26 | Vartharaj et al. (2020) | NA | NA | NA |